Collaboration hopes to improve paediatric drug development

Site management organisation Penta ID Innovation and contract research organisation (CRO) Cromsource have announced a partnership to help improve paediatric drug development. 

The collaboration will utilise Penta’s expertise in paediatric infectious diseases and Cromsource’s capabilities in managing worldwide drug development to address the challenges in bringing new therapies to children. 

“We are thrilled to partner with such a prestigious and dynamic organisation,” said Oriana Zerbini, CEO of Cromsource. “The partnership will enable us to share scientific, therapeutic, regulatory and operational expertise, creating a high-quality, highly scalable clinical development capability for paediatric research. Our strategic partnership will accelerate the availability of new products to address unmet medical needs of children around the world.” 

Penta ID Innovation CEO, Luigi Comacchio, said: ”Cromsource is an ideal partner for Penta ID Innovation because of its proven track record of quality in addition to its attention to detail and commitment to delivery of services at every phase of clinical development.”